Literature DB >> 20451335

Breast cancer screening in the older woman: an effective way to reduce mortality?

M Paesmans1, L Ameye, M Moreau, S Rozenberg.   

Abstract

The value of systematic mammographic screening has been studied in a total of 11 randomized trials - some of doubtful methodological quality - on various populations of women; the earliest dates from the 1960s. However, older women have been under-represented in these trials, as only six of them registered patients over 60 years of age. The proportion of women aged over 70 years was low and there are no data for patients older than 74. Several meta-analyses have been conducted and a plausible estimate of the impact of screening is a 16% reduction in breast cancer mortality (95% confidence interval 9-23%). Some meta-analyses provide "post hoc subgroup analyses" by age and these have found a greater benefit of screening for women of older age, with estimates of risk reductions of 17%, 27% and 22% for cohorts of women aged 55-64, 60-69 and 65-74; these figures are significantly different from 0. In comparison, for women in the age groups 40-49, 45-54 and 50-59 the estimated risk reductions were 9%, 7% and 12%. Nevertheless, there has been no formal demonstration of an interaction with age. When these estimates are translated into the number of women who need to be screened in order to avoid one death from breast cancer during 15 years of follow-up, the figure lies between 1370 and 4120. The probability of not dying from breast cancer within 15 years of screening for a 65-year-old woman is estimated to be in the range 98.85-99.11%, compared with 98.73% for a woman who does not undergo screening. These benefits should be balanced against the possible disadvantages of screening, including false positive results, overdiagnosis and overtreatment. One of the meta-analyses concluded that the rate of total mastectomies was significantly increased after screening. Although most scientific recommendations agree that screening should be proposed to all women aged 50-69 years, the benefits and disadvantages of mammography should be fully explained, in order to allow them to make a truly informed decision. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20451335     DOI: 10.1016/j.maturitas.2010.03.016

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  4 in total

1.  Associated morbidity in screened and diagnosed breast cancer patients: a retrospective study.

Authors:  Diane Bula-Ibula; Birgit Carly; Serge Rozenberg
Journal:  Arch Gynecol Obstet       Date:  2022-08-05       Impact factor: 2.493

2.  Comparison of pathologic characteristics of breast cancer in younger and older women.

Authors:  Reza Yazdani-Charati; Karimollah Hajian-Tilaki; Majid Sharbatdaran
Journal:  Caspian J Intern Med       Date:  2019

3.  Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study.

Authors:  Nienke A de Glas; Anton J M de Craen; Esther Bastiaannet; Ester G Op 't Land; Mandy Kiderlen; Willemien van de Water; Sabine Siesling; Johanneke E A Portielje; Herman M Schuttevaer; Geertruida Truuske H de Bock; Cornelis J H van de Velde; Gerrit-Jan Liefers
Journal:  BMJ       Date:  2014-09-14

4.  Response costs of mammography adherence: Iranian women's perceptions.

Authors:  Mahsa Khodayarian; Seyed Saied Mazloomi-Mahmoodabad; Minoor Lamyian; Mohammad Ali Morowatisharifabad; Hossein Tavangar
Journal:  Health Promot Perspect       Date:  2016-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.